Scott Tarriff, CEO at EAGLE PHARMACEUTICALS, INC. (EGRX), sold 60,000 shares at $21.06 ($1.2M) on 2023-05-15, disclosed to the SEC on 2023-05-15.
Open-market sale of $1.2M EGRX by CEO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.71 | 15,000 | $311K | 25.2% |
| 2 | $19.69 | 3,131 | $62K | 5.0% |
| 3 | $19.69 | 3,131 | $62K | 5.0% |
| 4 | $20.42 | 11,869 | $242K | 19.6% |
| 5 | $20.42 | 11,869 | $242K | 19.6% |
| 6 | $21.06 | 14,800 |
| $312K |
| 25.2% |
| 7 | $21.52 | 200 | $4K | 0.3% |
| Total | $20.58 avg | 60,000 | $1.2M | 100% |
| Filing → |
| EGRX | SELL | 2023-05-18 | $300K | — | Filing → |
| EGRX | SELL | 2019-04-03 | $2.5M | — | Filing → |
| EGRX | SELL | 2019-03-04 | $1.9M | — | Filing → |